Recent developments of Sugammadex Sodium in the wake period of anesthesia

Sugammadex Sodiumis a novel antagonist of selective non-depolarizing muscle relaxants (myorelaxants), which was first reported in humans in 2005 and has since been used clinically in Europe, the United States and Japan. Compared with traditional anticholinesterase drugs, it can antagonize deep

2021 FDA New Drug Approvals 1Q-3Q

Innovation drives progress. When it comes to innovation in the development of new drugs and therapeutic biological products, FDA's Center for Drug Evaluation and Research (CDER) supports the pharmaceutical industry at every step of the process. With its understanding of the science used to creat

Recent developments of Sugammadex Sodium in the wake period of anesthesia

Sugammadex Sodiumis a novel antagonist of selective non-depolarizing muscle relaxants (myorelaxants), which was first reported in humans in 2005 and has since been used clinically in Europe, the United States and Japan. Compared with traditional anticholinesterase drugs, it can antagonize deep

Which tumors are thalidomide effective in treating!

Thalidomideis effective in treating these tumors!1. In which solid tumors can thalidomide be used.1.1. lung cancer.1.2. Prostate cancer.1.3. nodal rectal cancer.1.4. hepatocellular carcinoma.1.5. Gastric cancer.2. Thalidomide in tumor cachexiaOncologic cachexia, an advanced cancer syndrome cha

Apixaban and Rivaroxaban

In recent years, the sales ofapixabanhave grown rapidly, and the global market has already surpassedrivaroxaban. Because Eliquis (apixaban) has an advantage over warfarin in preventing stroke and bleeding, and Xarelto (Rivaroxaban) only showed non-inferiority. In addition,&nb

Obeticholic acid

On June 29,Intercept Pharmaceuticals announcedthat it has received a complete new drug application from the US FDA regarding its FXR agonist obeticholic acid (OCA) for fibrosis caused by non-alcoholic steatohepatitis (NASH) Response letter (CRL). The FDA stated in the CRL that based on t